News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oxford Gene Technology Ltd. Awarded ISO/IEC 17025:2005 Accreditation, Signifying Technical Expertise



2/15/2011 10:35:11 AM

Oxford, UK – 15th February 2011. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, today announced that its Genefficiency™ and CytoSure™ array comparative genomic hybridization (aCGH) services have been accredited as meeting ISO/IEC 17025:2005 international standards by the United Kingdom Accreditation Service (UKAS). The award underlines the superior level of expertise and quality control in the company’s laboratories and allows identification of OGT as a high-quality supplier of fully validated aCGH services. The endorsement is one of a trio recently achieved by the company, forming part of a programme of initiatives aimed at providing independent affirmation of OGT’s working practices. This new accreditation aligns with the recently received ISO 9001 and ISO 27001 certifications, highlighting OGT’s dedication to the maintenance of high-quality management processes and stringent information security.

Dr Mike Evans, OGT’s CEO, commented: “Accreditation of OGT’s Genefficiency and CytoSure aCGH services further emphasises the company’s commitment to offering customers the best and most reliable solutions possible. It also proves that the company can provide the necessary structure and skills to offer its specialist services as part of a clinical diagnostic workflow.”

The ISO 17025 standard relates to laboratory testing, including the competence of laboratory staff, validity and traceability of technical results, as well as proficiency in testing using standard and laboratory-developed methods. The accreditation was awarded to OGT after a detailed external audit by UKAS that covered sample tracking and processing, data analysis, quality control, traceability, business continuity, staff training, as well as OGT’s general quality and security policies. For further information on OGT’s products and services, please visit www.ogt.co.uk/pr/iso.

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk W: www.ogt.co.uk

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.

CytoSure™: For research use only

This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

About UKAS

The United Kingdom Accreditation Service is the sole national accreditation body recognised by government to assess, against internationally agreed standards, organisations that provide certification, testing, inspection and calibration services. Accreditation by UKAS demonstrates the competence, impartiality and performance capability of these evaluators. UKAS is a non-profit-distributing private company, limited by guarantee. UKAS is independent of Government but is appointed as the national accreditation body by the Accreditation Regulations 2009 (SI No 3155/2009) and operates under a Memorandum of Understanding with the Government through the Secretary of State for Business, Innovation and Skills.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES